2025年肌少症数位治疗药物全球市场报告

近年来，数位疗法治疗肌少症的市场规模迅速扩张，从2024年的13.2亿美元成长到2025年的15.4亿美元，复合年增长率达16.3%。这段历史时期的成长可归因于多种因素，例如人口老化加剧、老龄化相关性肌肉萎缩盛行率上升、人们对肌肉减少症的认识不断提高、远距远端医疗服务的普及、家庭復健解决方案需求的不断增长以及政府推动数位医疗的支持倡议。

预计未来几年，数位疗法治疗肌少症市场将快速成长，到2029年将达到27.8亿美元，复合年增长率为16.0%。预测期间的成长可归因于多种因素，例如人口老化、人们对预防性肌肉健康的兴趣日益浓厚、人工智慧在数位疗法中的整合度不断提高、数位疗法（DTx）报销政策的扩大、个人化运动计画的开发、科技公司与医疗服务提供者之间伙伴关係的加强，以及对远距復健解决方案的需求不断增长。这段时期的主要趋势包括：基于人工智慧的个人化运动计画的进步、与穿戴式健康追踪器的整合、远距復健平台的扩展、在老年护理中的应用、远端患者监护的增强以及数位健康解决方案的创新。

肌少症的数位疗法是经过临床检验的、由软体主导的干预措施，旨在预防、管理和治疗肌少症。肌少症是一种以肌肉质量、力量和功能进行性丧失为特征的疾病。这些疗法基于临床证据和行为科学，并利用数位平台提供个人化治疗策略。

肌少症数位疗法的主要产品包括软体、设备和服务。该软体透过数位装置提供客製化的干预措施，例如运动计划和营养计划，以管理肌肉流失并支持復健。这些解决方案透过线上平台、药局和其他管道销售，涵盖肌肉强化、体力活动监测和营养管理等活动。最终使用者包括医院、诊所、家庭护理机构和復健中心。

2025年春季美国突然提高关税以及由此引发的贸易摩擦对医疗保健产业产生了严重影响，特别是对关键医疗设备、诊断设备和药品的供应。医院和医疗机构面临进口手术器械、影像设备以及注射器和导管等消耗品成本上涨的问题。这些成本上涨给医疗保健预算带来了压力，导致一些医疗机构推迟设备升级或将成本转嫁给患者。此外，原料和零件的关税阻碍了基本药品和医疗设备的生产，造成了供应链瓶颈。作为应对措施，该行业正在筹资策略多样化，尽可能促进本地生产，并倡导对紧急医疗产品免关税。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供数位治疗肌少症市场统计数据，例如全球市场规模、区域份额、竞争对手在数位治疗肌少症市场的份额、详细的数位治疗肌少症细分市场、市场趋势和商业机会。本数位治疗肌少症市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的一切观点。

合併症盛行率的上升预计将推动肌少症数位疗法市场的未来成长。合併症是指两种或两种以上健康状况同时存在于一个人身上。随着人口老化，由于生理功能下降和长期暴露于健康风险中，罹患多种慢性疾病的风险增加。肌少症的数位疗法透过促进规律运动和肌肉强化、改善新陈代谢和减少脂肪堆积，可有效预防併发症，尤其是肥胖。例如，总部位于英国的会员组织世界肥胖联合会在 2024 年 3 月报告称，到 2035 年，预计约 79% 的超重和肥胖成年人居住在中低收入国家，肥胖成年人总数预计将达到 15.3 亿。因此，併发症的上升支持了肌少症数位疗法市场的成长。

肌少症数位疗法市场的关键公司正专注于开发先进的解决方案，例如药物发现平台，以开发更有针对性的治疗方法，提高治疗效果，并加速与老龄化相关的肌肉损失的个人化治疗。药物发现平台透过使用先进的工具和方法，可以更快、更有效地识别和开发药物。例如，2025 年 4 月，以色列生物技术公司 ProFuse Technology 宣布了一个药物发现平台，旨在预防因 GLP-1减重药、老化（肌少症）和癌症恶病质引起的肌肉损失。透过使用实验室培育的、模仿天然肌肉的高度成熟的肌肉组织，该公司可以更准确、更有效地测试和筛检候选药物。这个创新平台减少了对动物测试的依赖并降低了研究成本。随着对肌肉保存治疗方法的需求不断增长，ProFuse 正在将其业务从培养肉扩展到生物製药，提供一种开创性的方法来解决日益严重的肌肉健康挑战。

2023年8月，美国製药公司礼来公司以19亿美元收购了Versanis Bio。此次收购扩大了礼来的产品组合，Versanis的主导产品比麦格鲁单抗目前正在进行单独或与Semaglutide联合治疗超重或肥胖患者的2b期临床试验。 Versanis Bio是一家总部位于美国的製药公司，专注于开发治疗肌少症的药物，此次收购将增强礼来在肥胖和肌肉减少治疗领域的实力。

数位疗法肌少症市场由提供软体主导治疗性介入、预测分析整合和復健交付等服务的营业单位所获得的收益所构成。市场价值还包括服务供应商销售或包含在其服务产品中的相关产品的价值。数位疗法肌少症市场还包括穿戴式装置、生物感测器以及虚拟和扩增实境工具的销售。该市场的价值是指“出厂价”，即产品製造商或创造者向其他营业单位（包括下游製造商、批发商、经销商和零售商）或直接向最终客户销售的产品价值。该市场中的产品价值还包括产品创造者销售的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

• 全球数位治疗肌少症：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
• 最终用途产业分析
• 全球数位治疗肌少症市场：成长率分析
• 全球数位治疗肌少症市场表现：规模与成长，2019-2024 年
• 全球数位治疗肌少症市场预测：规模与成长，2024-2029 年，2034 年
• 全球肌少症数位疗法：总潜在市场（TAM）

第六章 市场细分

• 全球数位治疗肌少症市场：按产品、绩效和预测，2019-2024 年、2024-2029 年、2034 年
• 软体
• 装置
• 服务
• 全球数位治疗药物肌少症市场：按分销管道、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 线上平台
• 药局
• 其他分销管道
• 全球数位治疗肌少症市场：依应用、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 肌肉强化
• 体力活动监测
• 营养管理
• 其他用途
• 全球数位治疗肌少症市场：按最终用户、绩效和预测，2019-2024 年、2024-2029 年、2034 年
• 医院和诊所
• 居家照护环境
• 復健中心
• 其他最终用户
• 全球数位治疗肌少症市场：按软体（类型）、表现和预测细分，2019-2024 年、2024-2029 年、2034 年
• 行动应用程式
• 网路为基础的平台
• 人工智慧监控工具
• 运动和復健计划
• 营养指导软体
• 全球数位治疗肌少症市场：按设备（类型）细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 穿戴式健身追踪器
• 智慧秤
• 连接阻力带
• 肌电图（EMG）设备
• 肌力评估工具
• 全球数位治疗肌少症市场：按服务类型、绩效和预测细分，2019-2024 年、2024-2029 年、2034 年
• 远端患者监护服务
• 虚拟物理治疗课程
• 远距会诊服务
• 个人化辅导服务
• 数据分析和报告服务

第七章 区域和国家分析

• 全球数位治疗肌少症市场：区域表现与预测，2019-2024 年、2024-2029 年、2034 年
• 全球数位治疗肌少症市场：国家、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

• 数位治疗肌少症市场：竞争格局
• 数位治疗肌少症市场：公司简介
  • Noom Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sword Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Biofourmis Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Hinge Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Omada Health Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

• Virta Health Corp.
• Evolv Rehabilitation Technologies Ltd.
• Click Therapeutics Inc.
• DarioHealth Corp.
• WellDoc Inc.
• Propeller Health
• Lark Technologies Inc.
• mySugr GmbH
• SilverCloud Health Limited（a part of Amwell）
• Kaia Health Software GmbH
• Liva Healthcare A/S
• Zibrio Inc.
• Gait Up SA
• Noraxon Inc.
• Mira Rehab Limited

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

• 2029 年数位治疗肌少症市场：提供新机会的国家
• 2029 年肌少症数位治疗市场：细分领域带来新机会
• 2029 年肌少症数位治疗药物市场：成长策略
  • 基于市场趋势的策略
  • 竞争对手策略

第36章 附录

Digital therapeutics for sarcopenia refer to clinically validated, software-driven interventions designed to prevent, manage, or treat sarcopenia, a condition marked by progressive loss of muscle mass, strength, and functionality. These interventions utilize digital platforms to deliver personalized treatment strategies based on clinical evidence and behavioral science.

The primary products of digital therapeutics for sarcopenia include software, devices, and services. The software delivers tailored interventions such as exercise programs and nutrition plans via digital devices to help users manage muscle loss and support recovery. These solutions are distributed through online platforms, pharmacies, and other channels, with applications including muscle strengthening, physical activity monitoring, and nutrition management. End users include hospitals, clinics, homecare settings, rehabilitation centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The digital therapeutics sarcopenia market research report is one of a series of new reports from The Business Research Company that provides digital therapeutics sarcopenia market statistics, including the digital therapeutics sarcopenia industry global market size, regional shares, competitors with the digital therapeutics sarcopenia market share, detailed digital therapeutics sarcopenia market segments, market trends, and opportunities, and any further data you may need to thrive in the digital therapeutics sarcopenia industry. This digital therapeutics sarcopenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The digital therapeutics sarcopenia market size has grown rapidly in recent years. It will grow from $1.32 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to the increasing aging population, rising prevalence of age-related muscle loss, growing awareness of sarcopenia, expanding adoption of telehealth services, rising demand for home-based rehabilitation solutions, and supportive government initiatives promoting digital healthcare.

The digital therapeutics sarcopenia market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to the rising aging population, increasing focus on preventive muscle health, growing integration of AI in digital therapeutics, expanding reimbursement policies for digital therapeutics (DTx), development of personalized exercise programs, strengthening partnerships between technology firms and healthcare providers, and rising demand for remote rehabilitation solutions. Major trends during this period include advancements in AI-driven personalized exercise programs, integration with wearable health trackers, expansion of tele-rehabilitation platforms, adoption in elderly care, enhanced remote patient monitoring, and innovations in digital health solutions.

The rising prevalence of comorbidities is expected to drive the growth of the digital therapeutics sarcopenia market going forward. Comorbidities refer to the coexistence of two or more health conditions in a single individual. The increase in comorbidities is primarily driven by the aging population, as advancing age raises the risk of developing multiple chronic conditions due to declining physiological functions and prolonged exposure to health risks. Digital therapeutics for sarcopenia are effective in preventing comorbidities, particularly obesity, by encouraging regular physical activity and muscle strengthening, which improve metabolism and reduce fat accumulation. For example, in March 2024, the World Obesity Federation, a UK-based membership organization, reported that nearly 79% of adults affected by overweight and obesity are projected to reside in low- and middle-income nations by 2035, with the total number of adults with obesity expected to reach 1.53 billion. Therefore, the rising prevalence of comorbidities is supporting the growth of the digital therapeutics sarcopenia market.

Key companies in the digital therapeutics sarcopenia market are focusing on developing advanced solutions, such as drug discovery platforms, to create more targeted therapies, improve treatment efficacy, and accelerate personalized care for age-related muscle loss. A drug discovery platform enables faster and more efficient identification and development of new drugs using advanced tools and methods. For instance, in April 2025, ProFuse Technology, an Israel-based biotechnology company, introduced a drug discovery platform aimed at preventing muscle loss caused by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By using lab-grown, highly mature muscle tissues that replicate natural muscle, the company can test and screen drug candidates more accurately and efficiently. This innovative platform reduces dependency on animal testing and lowers research costs. With rising demand for muscle-preserving therapies, ProFuse is expanding from cultivated meat into biopharma, offering a pioneering approach to tackle growing muscle health challenges.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Versanis Bio for $1.9 billion. This acquisition expanded Lilly's portfolio to include Versanis' main asset, bimagrumab, which is currently being evaluated in Phase 2b trials both alone and in combination with semaglutide for individuals with overweight or obesity. Versanis Bio, a US-based pharmaceutical company, specializes in developing therapies for sarcopenia, and this acquisition strengthens Eli Lilly's presence in treatments targeting obesity and muscle loss.

Major players in the digital therapeutics sarcopenia market are Noom Inc., Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Virta Health Corp., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Propeller Health, Lark Technologies Inc., mySugr GmbH, SilverCloud Health Limited (a part of Amwell), Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, and Cometa Srl.

North America was the largest region in the digital therapeutics sarcopenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in digital therapeutics sarcopenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the digital therapeutics sarcopenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The digital therapeutics sarcopenia market consists of revenues earned by entities by providing services such as software-driven therapeutic interventions, integration of predictive analytics, and delivery of rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics sarcopenia market also includes sales of wearable devices, biosensors, and virtual and augmented reality tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Digital Therapeutics Sarcopenia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on digital therapeutics sarcopenia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for digital therapeutics sarcopenia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The digital therapeutics sarcopenia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Software; Devices; Services
• 2) By Distribution Channel: Online Platforms; Pharmacies; Other Distribution Channels
• 3) By Application: Muscle Strengthening; Physical Activity Monitoring; Nutrition Management; Other Applications
• 4) By End User: Hospitals And Clinics; Homecare Settings; Rehabilitation Centers; Other End Users
• Subsegments:
• 1) By Software: Mobile Applications; Web-Based Platforms; AI-Powered Monitoring Tools; Exercise And Rehabilitation Programs; Nutritional Guidance Software
• 2) By Devices: Wearable Fitness Trackers; Smart Scales; Connected Resistance Bands; Electromyography (EMG) Devices; Muscle Strength Assessment Tools
• 3) By Services: Remote Patient Monitoring Services; Virtual Physiotherapy Sessions; Teleconsultation Services; Personalized Coaching Services; Data Analytics And Reporting Services
• Companies Mentioned: Noom Inc.; Sword Health Inc.; Biofourmis Inc.; Hinge Health Inc.; Omada Health Inc.; Virta Health Corp.; Evolv Rehabilitation Technologies Ltd.; Click Therapeutics Inc.; DarioHealth Corp.; WellDoc Inc.; Propeller Health; Lark Technologies Inc.; mySugr GmbH; SilverCloud Health Limited (a part of Amwell); Kaia Health Software GmbH; Liva Healthcare A/S; Zibrio Inc.; Gait Up SA; Noraxon Inc.; Mira Rehab Limited; Cometa Srl.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Digital Therapeutics Sarcopenia Market Characteristics

3. Digital Therapeutics Sarcopenia Market Trends And Strategies

4. Digital Therapeutics Sarcopenia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Digital Therapeutics Sarcopenia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Digital Therapeutics Sarcopenia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Digital Therapeutics Sarcopenia Market Growth Rate Analysis
• 5.4. Global Digital Therapeutics Sarcopenia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Digital Therapeutics Sarcopenia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Digital Therapeutics Sarcopenia Total Addressable Market (TAM)

6. Digital Therapeutics Sarcopenia Market Segmentation

• 6.1. Global Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Software
• Devices
• Services
• 6.2. Global Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Platforms
• Pharmacies
• Other Distribution Channels
• 6.3. Global Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Muscle Strengthening
• Physical Activity Monitoring
• Nutrition Management
• Other Applications
• 6.4. Global Digital Therapeutics Sarcopenia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Homecare Settings
• Rehabilitation Centers
• Other End Users
• 6.5. Global Digital Therapeutics Sarcopenia Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mobile Applications
• Web-Based Platforms
• AI-Powered Monitoring Tools
• Exercise And Rehabilitation Programs
• Nutritional Guidance Software
• 6.6. Global Digital Therapeutics Sarcopenia Market, Sub-Segmentation Of Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wearable Fitness Trackers
• Smart Scales
• Connected Resistance Bands
• Electromyography (EMG) Devices
• Muscle Strength Assessment Tools
• 6.7. Global Digital Therapeutics Sarcopenia Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Remote Patient Monitoring Services
• Virtual Physiotherapy Sessions
• Teleconsultation Services
• Personalized Coaching Services
• Data Analytics And Reporting Services

7. Digital Therapeutics Sarcopenia Market Regional And Country Analysis

• 7.1. Global Digital Therapeutics Sarcopenia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Digital Therapeutics Sarcopenia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Digital Therapeutics Sarcopenia Market

• 8.1. Asia-Pacific Digital Therapeutics Sarcopenia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Digital Therapeutics Sarcopenia Market

• 9.1. China Digital Therapeutics Sarcopenia Market Overview
• 9.2. China Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Digital Therapeutics Sarcopenia Market

• 10.1. India Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Digital Therapeutics Sarcopenia Market

• 11.1. Japan Digital Therapeutics Sarcopenia Market Overview
• 11.2. Japan Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Digital Therapeutics Sarcopenia Market

• 12.1. Australia Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Digital Therapeutics Sarcopenia Market

• 13.1. Indonesia Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Digital Therapeutics Sarcopenia Market

• 14.1. South Korea Digital Therapeutics Sarcopenia Market Overview
• 14.2. South Korea Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Digital Therapeutics Sarcopenia Market

• 15.1. Western Europe Digital Therapeutics Sarcopenia Market Overview
• 15.2. Western Europe Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Digital Therapeutics Sarcopenia Market

• 16.1. UK Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Digital Therapeutics Sarcopenia Market

• 17.1. Germany Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Digital Therapeutics Sarcopenia Market

• 18.1. France Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Digital Therapeutics Sarcopenia Market

• 19.1. Italy Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Digital Therapeutics Sarcopenia Market

• 20.1. Spain Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Digital Therapeutics Sarcopenia Market

• 21.1. Eastern Europe Digital Therapeutics Sarcopenia Market Overview
• 21.2. Eastern Europe Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Digital Therapeutics Sarcopenia Market

• 22.1. Russia Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Digital Therapeutics Sarcopenia Market

• 23.1. North America Digital Therapeutics Sarcopenia Market Overview
• 23.2. North America Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Digital Therapeutics Sarcopenia Market

• 24.1. USA Digital Therapeutics Sarcopenia Market Overview
• 24.2. USA Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Digital Therapeutics Sarcopenia Market

• 25.1. Canada Digital Therapeutics Sarcopenia Market Overview
• 25.2. Canada Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Digital Therapeutics Sarcopenia Market

• 26.1. South America Digital Therapeutics Sarcopenia Market Overview
• 26.2. South America Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Digital Therapeutics Sarcopenia Market

• 27.1. Brazil Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Digital Therapeutics Sarcopenia Market

• 28.1. Middle East Digital Therapeutics Sarcopenia Market Overview
• 28.2. Middle East Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Digital Therapeutics Sarcopenia Market

• 29.1. Africa Digital Therapeutics Sarcopenia Market Overview
• 29.2. Africa Digital Therapeutics Sarcopenia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Digital Therapeutics Sarcopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Digital Therapeutics Sarcopenia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Digital Therapeutics Sarcopenia Market Competitive Landscape And Company Profiles

• 30.1. Digital Therapeutics Sarcopenia Market Competitive Landscape
• 30.2. Digital Therapeutics Sarcopenia Market Company Profiles
  • 30.2.1. Noom Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sword Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Biofourmis Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Hinge Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Omada Health Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Digital Therapeutics Sarcopenia Market Other Major And Innovative Companies

• 31.1. Virta Health Corp.
• 31.2. Evolv Rehabilitation Technologies Ltd.
• 31.3. Click Therapeutics Inc.
• 31.4. DarioHealth Corp.
• 31.5. WellDoc Inc.
• 31.6. Propeller Health
• 31.7. Lark Technologies Inc.
• 31.8. mySugr GmbH
• 31.9. SilverCloud Health Limited (a part of Amwell)
• 31.10. Kaia Health Software GmbH
• 31.11. Liva Healthcare A/S
• 31.12. Zibrio Inc.
• 31.13. Gait Up SA
• 31.14. Noraxon Inc.
• 31.15. Mira Rehab Limited

32. Global Digital Therapeutics Sarcopenia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Digital Therapeutics Sarcopenia Market

34. Recent Developments In The Digital Therapeutics Sarcopenia Market

35. Digital Therapeutics Sarcopenia Market High Potential Countries, Segments and Strategies

• 35.1 Digital Therapeutics Sarcopenia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Digital Therapeutics Sarcopenia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Digital Therapeutics Sarcopenia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer